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Abstract. The present study was designed to clarify 
the in vivo function of trkA as an NGF receptor in 
mammalian neurons. Using the rat sciatic nerve as a 
model system, we examined whether trkA is retro- 
gradely transported and whether transport is influ- 
enced by physiological manipulations. Following nerve 
ligation, trkA protein accumulates distal to the ligation 
site as shown by Western blot analysis. The distally ac- 
cumulating trkA species were tyrosine phosphorylated. 
The trkA retrograde transport and phosphorylation 
were enhanced by injecting an excess of NGF in the 
footpad and were abolished by blocking endogenous 
NGF with specific antibodies. These results provide 
evidence that, upon NGF binding, trkA is internalized 
and retrogradely transported in a phosphorylated state, 
possibly together with the neurotrophin. Furthermore, 
our results suggest that trkA is a primary retrograde 
NGF signal in mammalian neurons in vivo. 
N 
'Gr,  the  prototype  of a  family of closely related 
polypeptide growth factors including brain-derived 
neurotrophic  factor  (BDNF) 1,  neurotrophin-3 
(NT-3), and neurotrophin-4/5 (NT-4/5), stimulates the dif- 
ferentiation, maintains the  phenotype, and supports  the 
survival of distinct populations of neurons (34--36, 57). In 
general, neurotrophins interact with two different types of 
cell surface receptors present on responsive neurons. The 
first described receptor corresponds to a 75- to 80-kD inte- 
gral membrane glycoprotein (p75 NGFa) that binds all neu- 
rotrophins with equal affinity (9,  45).  A  second type of 
NGF receptor has been identified as the product of the 
proto-oncogene trkA, a  member of the trk family of ty- 
rosine kinase receptors (25, 28). The trkA gene product is 
a  140-kD  integral membrane glycoprotein with tyrosine 
kinase activity (26, 39). Two trkA-related genes, trkB and 
trkC,  were  subsequently  cloned  and  shown  to  encode 
high-affinity receptors for BDNF and NT-4/5 (51, 52) and 
NT-3  (21,  32),  respectively. Although considerable cross 
talk exists between the neurotrophin ligands and their re- 
ceptors,  there is clear receptor preference for particular 
neurotrophins (21).  The neurotrophin specificity of trkA 
Address all correspondence to: Vassilis E. Koliatsos, M.D., Neuropathol- 
ogy Laboratory,  The Johns Hopkins  University School of Medicine, 558 
Ross Research Bldg., 720 Rutland Ave., Baltimore, MD 21205-2196. Tel.: 
(410) 955-5632. FAX: (410) 955-9777. 
1. Abbreviations used in this paper: BDNF, brain-derived  neurotrophin-4/ 
5, DRG, dorsal root ganglia; NT-3, neurotrophin-3;  NT°4/5, neurotrophin- 
4/5; SNT, suc-associated  neurotrophic factor-induced tyrosine-phosphory- 
lated target. 
may also be determined by the relative cellular expression 
levels of p75 N6FR and trkA (1). Efforts to elucidate the sig- 
nal transduction pathways used by NGF receptors have in- 
volved PC12 cells, primary neuron cultures, or fresh tissue 
sections. In these systems, NGF rapidly stimulates the ty- 
rosine phosphorylation and activation of trkA (3, 26, 28, 
29, 38, 62). The phosphorylation of trkA results in activa- 
tion of several signaling proteins via phosphorylation, as 
well as the induction of immediate early genes (reviewed 
in reference 4  and 8).  Stable neuronal differentiation of 
PC12 cells requires the trk-mediated tyrosine phosphory- 
lation of SHC and PLC-1 and the activity of ras (53, 58, 
63).  The  specificity of NGF-mediated responses in neu- 
ronal cells may be determined in part by distinctive targets 
of  neurotrophic  factor-induced  tyrosine  kinase  activity, 
such as the recently identified suc-associated neurotrophic 
factor-induced tyrosine-phosphorylated target (SNT) pro- 
tein (42). 
Neuronal terminals, the sites of neurotrophin/receptor 
interaction, are often many centimeters away from the cell 
body, a condition that necessitates signal transduction via 
retrograde axonal transport (30).  Retrograde messengers 
in the NGF signal transduction cascade (e.g., an activated 
receptor complex, an activated downstream kinase, or a 
second messenger molecule) are currently unknown. Ex- 
ogenously administered  [125I]NGF is  retrogradely trans- 
ported in a specific saturable manner by sympathetic and 
sensory neurons (18, 54)  as well as some central neurons 
(7, 49).  Indeed, this technique has been used to identify 
novel  neurotrophin-responsive  populations  of  neurons 
(30),  including cholinergic neurons of the basal forebrain 
(48). Although NGF itself is retrogradely transported, the 
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rotrophic signal (19), demonstrating that NGF itself is not 
the  intracellular  retrograde  signal  and  suggesting  that 
some other receptor-generated messenger is retrogradely 
transported from the nerve terminal to the cell body. 
It has been suggested that the retrograde transport of 
NGF is initiated by endocytic internalization of the ligand- 
receptor  complex (30),  presumably following binding to 
high-affinity  receptors (2). The present study was designed 
to  determine  whether  trkA  is  retrogradely  transported 
and whether such transport is physiologically relevant to 
neurotrophin signal transduction. To address these ques- 
tions, we performed sciatic nerve ligations in conjunction 
with immunoblot analysis of trkA in nerve segments distal 
to the ligation to determine whether this receptor accumu- 
lates in a way that suggests retrograde transport. To assess 
the physiological significance of the retrograde transport 
of trkA, we determined the effect of footpad injection of 
NGF and anti-NGF antibodies on levels of trkA in various 
segments of the sciatic nerve as well as the phosphoryla- 
tion state of this receptor. The results of these studies indi- 
cate that trkA is retrogradely transported in adult mam- 
malian axons  and that retrogradely transported  trkA is 
tyrosine  phosphorylated.  Blocking  target-derived  NGF 
with anti-NGF antibodies eliminates the retrograde trans- 
port and phosphorylation of trkA, whereas the saturation 
of sensory  terminals  with  an  excess  of NGF  enhances 
transport and phosphorylation. These experiments suggest 
that trkA is a primary retrograde NGF signal effector in 
vivo. 
Materials and Methods 
trk Antisera 
Anti-pantrk 203 antibody was generated against the COOH-terminal 14 
amino acids of human trk (17).  Antibodies against this peptide recognize 
trkA, trkB, and trkC (26, 28, 51, 59). The first specific trkA antibody was 
generated in rabbits using a peptide encoding amino acids 488-507  in the 
juxtamembrane region of human trkA (FMTLGGSSLSPTEGKGSGLE).  This an- 
tibody is referred to here as anti-trkA 488--507. The specificity of trk anti- 
bodies was assessed using detergent lysates of Sf9 insect cells infected with 
recombinant baculovirus encoding human trkA (R. Stephens and D. Kap- 
lan,  unpublished observations), rat  trkB  (R.  Stephens and  D.  Kaplan, 
unpublished observations), or rat trkC  (P. Tsouifas and L. Parada,  un- 
published observations). The anti-trkA 488-507 antibody specifically rec- 
ognized a prominent 140-kD band and possibly a faint 160--180-kD band 
only in trkA-expressing Sf9 cell lysates (Fig. 1, lanes 1-3). The anti-pantrk 
203  antibody recognized prominent 140-150-kD  bands in trkA-, trkB-, 
and trkC-expressing Sf9 cells, lysates, and possibly a faint 180-kD band 
only in trkA-expressing SF9 cell lysates (Fig. 1, lanes 4--6). Antibodies to 
trk were used for immunoblotting as previously described (17, 26) at dilu- 
tions of 1:2,000 to 1:3,000 (Fig. 1). A second trkA-specific antibody used in 
the present study, referred to as RTA, was generated in rabbits using a fu- 
sion protein, purified from a baculovirus-Sf9 cell expression system, which 
corresponds to the entire NH2-terminal domain of trkA (amino acids 1--416). 
The generation and specificity of this antibody has been previously de- 
scribed (6). 
Sciatic Nerve Ligations and Footpad Injections 
Adult male Sprague-Dawley rats were anesthetized with nitrous oxide/ox- 
ygen/ethrane at a 66:33:1 ratio, and the sciatic nerve was exposed. Two lig- 
atures, 2 mm apart, were placed at the level of the mid sacroiliac synosteo- 
sis following sacroiliac disarticulation. Immediately after nerve ligation, 
injections of either saline (200 I~l), NGF (80 p,g in 200 i~1PBS; Genentech, 
South San Francisco, CA) or anti-NGF antiserum (100 p~l serum in 100 i~l 
PBS) were made into the ipsilateral footpad. After 18 h, rats were killed 
Figure 1. Specificity of trk antibodies. Lysates of Sf9 cells express- 
ing  trkA,  trkB,  or  trkC  were  electrophoresed  on  SDS-poly- 
acrylamide  gels  and  transferred  to  nitrocellulose  membrane. 
Membranes were probed with anti-trkA  488-507  (lanes 1-3)  or 
anti-pantrk  203  (lanes  4-6)  antibodies.  Positions  of prominent 
trkA proteins are indicated by double arrowheads. 
by decapitation, and 8-mm nerve segments were taken at successive sites 
proximal and distal to the ligature. Nerve sections were immediately fro- 
zen on dry ice and stored for later preparation as described below. The 
previous experiment was repeated three times and all segments from all 
animals from each experiment were processed in the same blot. 
Tissue Sample Preparation 
Tissue was prepared by washing once with cold PBS and once with cold 
TBS and homogenizing in cold TBS with 1% NP-40, 10% glycerol, 1 mM 
PMSF (Sigma Chemical Co., St.  Louis, MI), 10 v,g/ml aprotinin (Boeh- 
ringer Mannheim Corp., Indianapolis, IN), 1 ~g/ml leupeptin (Boehringer 
Mannheim), and 500  wM orthovanadate (Sigma) with a probe sonieator 
for 30 s. Homogenates were spun at 10,000 rpm for 10 rain at 4°C, and the 
supernatant was subjected to either immunoprecipitation or SDS-PAGE. 
Equal protein quantities were determined by the BCA method (Pierce 
Chemical Company, Rockford, IL) and by immunoblot analysis for mye- 
lin basic protein. Briefly, nerve segment homogenates were diluted seri- 
ally and applied to a nitrocellulose membrane by vacuum suction on a dot 
blot  apparatus  (Bio-Rad  Labs.,  Richmond,  CA).  Nitrocellulose  mem- 
branes were then probed with the mouse monoclonal antibody SM199, di- 
rected against myelin basic protein (Sternberger Monoclonals, Inc., Balti- 
more, MD) followed by HRP-conjugated goat anti-mouse immunoglobulin 
(Kirkegaard & Perry Labs., Inc., Gaithersburg, MD), and immunoreactive 
spots were visualized with ECL  (Amersham Corp., Arlington Heights, 
IL). Dilutions required to abolish visualization of myelin basic protein im- 
munoreactivity were used to indicate equal lengths of nerve in different 
segments.  Quantitative  experimental comparisons  between nerve  seg- 
ments were then performed only on samples on the same blot as described 
below. 
Immunoblotting and lmmunoprecipitation 
For pantrk  and trkA immunoblots, protein samples were separated by 
SDS-PAGE and transferred to nitrocellulose as described previously (14). 
Nitrocellulose membranes were blocked with 5% milk and incubated with 
pantrk and trkA antisera at a  1:2,500 dilution overnight at 4°C.  Immu- 
noreactive protein bands were visualized using HRP-linked goat anti-rab- 
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of supernatant from tissue  homogenates (25-50  ~,g protein) were pre- 
cleared with 30 ~1 of a 50% suspension of protein A-Sepharose (Pharma- 
cia LKB Biotechnology  Inc., Piscataway. NJ) containing  1% BSA in 50 
mM Tris-Cl (pH 8,0), 150 mM NaCI, and 5 mM EDTA. Supernatants from 
the precleared homogenates were incubated with 4 ~1 of rabbit pantrk an- 
tibody overnight at 4°C. Following antibody incubation, 30 gA of the pro- 
tein A-Sepharose solution mentioned above was added, and the mixture 
was incubated for 1 h at 4°C. Protein A~;epharose beads were then spun 
down and washed three times with 50 mM Tris-Cl (pH 8.0), 150 mM NaCI, 
and 5 mM EDTA.  Immunoprecipitated  proteins were analyzed by SDS- 
PAGE and phosphotyrosine  immunoblot using the mouse monoclonal an- 
tibody 4G10 (UBI, Lake Placid, NY) at a 1:1,000 dilution. 
Reverse Transcriptase-Polymerase  Chain Reaction 
(RT-PCR) Analysis 
Total RNA was isolated from adult rat dorsal root ganglia (DRG) by the 
RNAzol method (Tel Test, Inc., Freadswood, TX) (5), and 0.5 IJ,  g was de- 
natured in PCR reaction buffer (Perkin-Elmer Cetus, Norwalk, CT) with 
0.5 pA RNase Block (Stratagene  Inc., La Jolla, CA) at 65°C for 3 min. RT 
was carried out in PCR reaction buffer with 28 pmol of antisense primer 
(5'-agccccagggatggcagatc-3') and 1 ~I M-MLV RT (GIBCO BRL, Gaith- 
ersburg, MD) with 2 mM of each deoxynucleotide  triphosphate at 42°C 
for 1 h. Heteroduplexes were melted by incubation  at 95°C for 5 h; 28 
pmol of sense primer (5'-ccagcgggatctgcaacggc-3') in PCR reaction buffer 
with 1 /zl AmpliTaq  polymerase  (Perkin-Elmer Cetus) was added.  PCR 
reactions  were cycled 40×  with annealing  and polymerization  tempera- 
tures of 58 and 72°C, respectively. Northern blotting total RNA from the 
DRG and ventral horn of an adult male Sprague-Dawley rat was isolated 
using the RNAzol B method as per manufacturer's instructions (Tel Test, 
Inc.)  (5). Total  RNA (15  Ixg), determined spectrophotometrically,  was 
electrophoresed on a 1% agarose, 2.2 M formaldehyde gel, transferred to 
a Nytran  (Schleichter  & Schuell, Inc., Keene, NH) nylon membrane in 
20× SSC overnight, and baked for 2 h at 80°C. For hybridization, a gel pu- 
riried 1.45-kb rat trkA insert corresponding to 40 amino acids of the extra- 
cellular domain and extending through the 3' untranslated region (40) was 
labeled with the random hexanucleotide  priming method to a specific ac- 
tivity of ~109 cmp per ~g and then diluted to 107 cpm per ml of hybridiza- 
tion buffer containing  500 mM sodium phosphate buffer (pH 7.2), 7% 
SDS, 1 mM EDTA, and 1% BSA. After preincubation  in hybridization 
buffer without probe for 3 h at 65°C, the membrane was incubated  over- 
night in hybridization  buffer containing  the labeled probe at 65°C. The 
next morning, the blot was washed once for 20 min at room temperature 
in 40 mM sodium phosphate buffer (pH 7.2), 5% SDS, 1 M EDTA, and 
0.5% BSA, followed by two washes, one at room temperature for 20 rain 
and one at 65°C for 10 min in 40 mM sodium phosphate buffer (pH 7.2), 
1% SDS, and 1 mM EDTA. The membrane was then exposed for 1 wk at 
70°C with intensifying screens and developed in an automatic film processor. 
In Situ Hybridization 
Riboprobes for rat trkA were transcribed  from a  1.45-kb cDNA insert 
corresponding  to the same region of trkA used for Northern hybridization 
subcloned into pBluescript KS  + (Stratagene)  using the Promega transcrip- 
tion kit as per manufacturer's instructions (Promega, Madison, WI). Anti- 
sense riboprobes (900 bp) were transcribed  with T7 RNA polymerase af- 
ter linearization  of the plasmid with ScaI, and 600-bp sense probes were 
transcribed using T3 RNA polymerase also after linearization of the plas- 
mid with Seal Transcription  reactions,  alkaline hydrolysis of fulMength 
probes, prehybridization,  and hybridization steps were carried out as pre- 
viously described (31). Thick sections (6 ~M) of fresh frozen DRG from 
an adult male Sprague-Dawley rat were cut on a cryostat, thaw mounted 
onto Vectabond (Vector Laboratories,  Inc.,  Burlingame,  CA)  subbed 
slides, and used for hybridization. 
Results 
Different Molecular Forms of trkA Are Present in 
Brain and in Neonatal and Adult Sensory Ganglia 
To determine the presence of trkA protein species in rat 
brain, DRG, and sciatic nerve, we performed immunoblot 
analysis on anterior brain, DRG, and sciatic nerve tissue 
homogenates using a trkA-specific antibody (Fig. 2). This 
analysis  revealed  the  presence  of  a  180-kD  species  in 
DRG (Fig. 2, A, left and B, lane 2) and adult sciatic nerve 
(Fig. 3 C, lane 1) and minor 140-kD and ll0-kD species in 
adult rat DRG (Fig. 2 B, lane 2). Similar analysis revealed 
trkA species in the 140- and ll0-kD range in adult rat an- 
terior brain homogenates (Figs. 2, A and B, lane 1), as well 
as in PC12 cell lysates and in primary DRG cultures from 
E15 rat embryos (data not shown). Dilution of the primary 
antibody resulted in disappearance of the 110-, 140-, and 
180-kD  bands  as did preincubation of the primary anti- 
body with the immunogenic peptide (Fig. 2 B). Further- 
more, immunoblot analysis of sciatic nerve homogenates 
with an additional trkA-specific antibody that recognizes 
an  extracellular  epitope  likewise  revealed  a  prominent 
Figure 2.  Immunoblot analysis of trkA species in newborn and 
adult rat sensory ganglia, sciatic nerve, and brain. In each case, 25 
~,g of total protein were loaded per lane. Positions of molecular 
mass markers (in kD)  are shown. (A)  Adult rat  anterior brain 
(Bar), sciatic nerve, and DRG and newborn rat trigeminal gan- 
glia were homogenized and subjected to immunoblot analysis us- 
ing anti-trkA 488-507 or anti-pantrk 203  antibodies as described 
in Materials and Methods. ABr and adult rat DRG samples were 
analyzed with both anti-trkA 488-507 (left) and anti-pantrkA 203 
(right).  Arrows indicate 140-  and 180-kD trkA species. (B) The 
specificity of the anti-trkA 488-507 antibody was tested by dilu- 
tion of the antibody and by blocking with 50 ixg/ml of the immu- 
nogenic peptide (lanes 1, 3, and 5 anterior brain; lanes 2, 4, and 6 
DRG). (C) The presence of trkA in P0 and adult trigeminal gan- 
glia was also determined by immunoblot analysis using the anti- 
trkA 488-507  antibody. Arrows in both B  and C indicate 180-kD 
species in DRG (left.pointing arrow) and 140-  and 110-kD trkA 
species in P0 and ABr (right-pointing arrows). The 110-kD spe- 
cies most  likely  represents under-glycosylated trkA  (39).  (D). 
The identity of the 180-kD trk species was further examined by 
immunoblot analysis of sciatic nerve homogenates. A  prominent 
180-kD species was observed in sciatic nerve (arrow), using either 
the anti-pantrk 203 antibody (lane 1) or RTA anti-trkA antibody 
(lane 2). 
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grade  transport  of  trkA  in 
sciatic  nerve  sensory  axons. 
(A)  The  trkA  mRNA  is 
present  in  adult  rat  DRG 
neurons. Sections of adult rat 
DRG were hybridized with a 
trkA-specific  probe.  The 
trkA mRNA is detectable in 
a large number of DRG neu- 
rons. (B) Source of trkA re- 
ceptors present in the sciatic 
nerve.  Total  RNA  (10  p,g) 
from adult rat DRG and ven- 
tral  horn  was  subjected  to 
Northern  analysis  using  a 
trkA-specific  probe.  The 
trkA mRNA is detectable in 
DRG,  but  not  in  ventral 
horn, as a single 3.5-kb band 
(arrow).  Positions  of  1.4- 
and  2.4-kb  markers  are 
shown. (C) Retrograde trans- 
port of phosphorylated trkA 
in the sciatic nerve. Segments 
of sciatic  nerve  immediately 
proximal to (P), and succes- 
sively distal from (D1, imme- 
diately distal; D2, far distal), 
a ligation site were homogenized and subjected to trkA immunoblot analysis using the anti-trkA 488-507 antibody (lanes 1-3) or immu- 
noprecipitation with the anti-pantrk 203 antibody followed by immunoblot analysis using the 4G10 antiphosphotyrosine antibody (lanes 
1' and 2'). The amount of protein loaded per lane (lanes 1-3) and subjected to immunoprecipitation (lanes 1' and 2') was normalized for 
nerve length, as described in Materials and Methods, and represented 10-20 Ixg in each case. Positions of molecular mass markers (in 
kD) are shown. Arrow indicates the position of trkA bands.  (D and E) The trkA species present in sciatic nerve represents transported, 
and not de novo, expressed receptors. (D) Total RNA (0.5 Ixg) from adult DRG was subjected to RT-PCR using rat trkA-specific sense 
and antisense primers. The identity of the amplified 527-bp fragment (arrow) was confirmed by restriction digest with both AccI (with 
expected fragment sizes of 241 and 286 bp) or BstXI (with expected fragment sizes of 153 and 374 bp). (E) The 527-bp fragment (arrow) 
characterized in D was amplified from RT-PCR reactions from DRG total RNA but not from total RNA isolated from a nerve segment 
immediately distal to the ligation site (D1), using the same primers as in D. Bar, 50 ~m. 
180-kD  trkA  species  (Fig.  2  D).  Immunoblotting with  a 
pantrk  antibody  that  recognizes  the  terminal  14-amino 
acid epitope of the trkA molecule also revealed the pres- 
ence of bands at 110 and 140 kD in anterior brain homoge- 
nates and 180 kD in DRG homogenates (Fig. 2 A, right). 
To  determine  whether  the  180-kD form of trkA we  ob- 
served  was specific for a  certain  developmental  stage  of 
sensory neurons,  we performed  immunoblot  analysis for 
trkA  on  trigeminal  ganglia  homogenates  from newborn 
and  adult  rats.  The  trkA  species  present  in  newborn 
trigeminal ganglia migrates at 110 and 140 kD, whereas a 
single 180-kD trkA species is seen in adult trigeminal gan- 
glia (Fig. 2 C). The ll0-kD band is most likely the undergly- 
cosylated form of trk originally observed in trkA-expressing 
fibroblasts  (39)  also seen  in PC12 cells  and brain tissues 
(17, 29). These results  raise  the possibility of differential 
trkA processing in neonatal and adult sensory neurons. 
trkA Is Expressed in Adult Rat DRG and Is 
Retrogradely Transported in Peripheral Nerve 
To determine  the  source  of trkA receptors  in the sciatic 
nerve, we performed trkA in situ hybridization on sections 
of adult rat DRG as well as trkA Northern blot analysis on 
total RNA isolated from adult DRG and ventral horn. Us- 
ing  a  trkA-specific  probe,  in  situ  hybridization  revealed 
the presence of trkA mRNA in DRG neurons (Fig. 3 A). 
The trkA mRNA  is present  as  a  single  3.5-kb species  in 
adult rat DRG (Fig. 3 B) and is absent from adult rat ven- 
tral  horn  (Fig.  3  B). To determine  whether  nerve  sheath 
cells could be the source of trkA receptors present in sci- 
atic nerve, we performed RT-PCR on total RNA isolated 
from normal adult rat sciatic nerve and a segment of nerve 
immediately distal to a ligation site. The latter experiment 
was designed  to determine  whether  the trkA gene is up- 
regulated in sheath cells in response to injury as has been 
reported  for p75  r~GFR (56).  A  527-bp species correspond- 
ing  to  the  trkA  PCR  product  was  amplified  from  total 
DRG  RNA but not from sciatic nerve  RNA  (Fig.  3  E). 
The identity of this 527-bp species was verified by restric- 
tion analysis (Fig. 3 D). The expression of the trkA gene in 
the  adult  DRG,  but  not  in  adult  ventral  horn  or sciatic 
nerve, demonstrates that trkA present in the adult rat sci- 
atic nerve must be derived from DRG neurons. To deter- 
mine whether trkA is transported retrogradely in periph- 
eral  axons,  sciatic nerve ligations  were performed  in  the 
adult rat. At 18 h  after ligation, small nerve segments (~8 
mm) were taken at various sites proximal and distal to the 
The Journal of Cell Biology, Volume 130, 1995  152 ligation site and processed for inununoprecipitation or im- 
munoblot analysis. TrkA was seen in the proximal and im- 
mediately distal nerve segments but was present in only 
small amounts in far distal segments (Fig. 3 C, lanes 1-3), 
suggesting that this protein is retrogradely transported. To 
determine the phosphorylation state of the trkA receptor 
in sciatic nerve segments, trk protein from the nerve seg- 
ments just proximal and just distal to the ligation site were 
immunoprecipitated from the homogenates with an anti- 
pantrk antibody that recognizes all members of the trk re- 
ceptor family.  These  immunoprecipitates  were  then  re- 
solved by SDS-PAGE and subjected to phosphotyrosine 
immunoblotting. A  180-kD tyrosine phosphorylated spe- 
cies was  observed in  both  nerve segments,  with signifi- 
cantly more of this species present in the immediately dis- 
tal  segment  than  in  the  immediately proximal  segment 
(Fig. 3  C, lanes 1' and 2'). Note that the total amount of 
trkA  in  the  proximal  segment  was  actually  somewhat 
higher than that in the immediately distal segment (Fig. 3 
C, lanes I  and 2). 
At the Nerve Terminal, NGF Stimulates and Anti-NGF 
Antibody Blocks the Retrograde Transport of trkA 
To address the physiological significance of the retrograde 
transport of trkA, NGF stimulation and blocking experi- 
ments were performed. Sciatic nerve ligations were per- 
formed as described above, this time followed by injection 
in the footpad of either saline, NGF, or anti-NGF antibod- 
ies. Footpad injection of NGF enhanced the distal  accu- 
mulation of trkA in the nerve (Fig. 4, A  and B; segments 
D1  and  D2,  top).  In  contrast, footpad injection of anti- 
NGF antibodies reduced the distal accumulation of trkA 
(Fig. 4, A and C; segments D1 and D2, top). These data in- 
dicate that the retrograde transport of trkA is stimulated 
by NGF and  blocked by anti-NGF antibodies delivered 
into the terminal field, consistent with a  ligand binding- 
mediated  mechanism  of retrograde transport.  To deter- 
mine whether the increased retrograde transport of trkA 
in response to NGF represents an enhanced transport of 
active trkA tyrosine kinase, the phosphorylation state of 
trkA in peripheral nerve segments was  assayed. The trk 
receptors  were  immunoprecipitated  from  sciatic  nerve 
segments  and  subjected to phosphotyrosine immunoblot 
analysis. Following footpad injection of NGF, an increase 
in the accumulation of tyrosine phosphorylated trkA was 
observed as compared to levels of phosphorylated trkA in 
the saline-injected control (Fig. 4, A  and B; segments D1 
and D2, bottom panels).  Conversely, anti-NGF antibody 
injection virtually abolished the distal accumulation of ty- 
rosine phosphorylated trkA (Fig. 4, A and C; segments D1 
and  D2, bottom panels).  These results demonstrate  that 
the retrograde transport of tyrosine phosphorylated (and 
presumably  enzymatically active)  trkA  is  dependent  on 
NGF present at the nerve terminal and suggest that this 
retrogradely transported trkA may serve as a signal from 
the terminal to the cell body. 
Discussion 
The present studies  demonstrate  that  trkA expressed in 
adult rat DRG neurons is retrogradely transported in a ty- 
Figure 4. Retrograde transport of trkA is influenced by physio- 
logically relevant manipulations. Proximal and distal segments of 
sciatic nerve following nerve ligation and footpad injection of ei- 
ther saline (A), NGF (B), or anti-NGF (C) antisera were homog- 
enized and subjected either to trkA immunoblot  analysis (A-C; 
top) or  pantrk  immunoprecipitation  followed  by immunoblot 
analysis using the 4G10 antiphosphotyrosine  antibody (A-C; bot- 
tom). Each lane  corresponds  to the nerve segment  illustrated 
above it (P, immediately proximal to ligature; D1, immediately 
distal to ligature; D2, far distal from ligature), and the amount of 
protein loaded or subjected to immunoprecipitation  was normal- 
ized for nerve length as described in the Materials and Methods 
(10-20 ~g in each case). 
rosine phosphorylated state and that the retrograde trans- 
port of trkA can be influenced by physiological manipula- 
tions of NGF in target fields. TrkA is present in adult rat 
DRG and sciatic nerve primarily as a 180-kD species. The 
migration of this species in polyacrylamide gels is different 
from that reported in PC12 cells (26), transfected NIH3T3 
cells (28), or primary cultures of embryonic rat DRG neu- 
rons  (Ehlers  and  Koliatsos,  unpublished  observations). 
However, higher molecular mass trk species of ~200 and 
280 kD have been reported in PC12 cells (15). These trk 
species bind NGF, are recognized by anti-trk antibodies, 
Ehlers et al. In Vivo Transport of trkA  153 and  are  phosphorylated on tyrosine upon binding NGF 
(15). Evidence in the present study indicating that the ob- 
served 180-kD species is trkA includes: the recognition of 
a 180-kD species in adult rat DRG by three different anti- 
bodies  directed  against  three  different  epitopes  of the 
trkA molecule, the ability of the immunogenic peptide to 
abolish binding of the trkA-specific antibody to the 180-kD 
band, the presence of a  180-kD tyrosine phosphorylated 
species in pantrk immunoprecipitates, and the  transport 
behavior of the 180-kD form of trkA in peripheral axons. 
Future studies will need to examine directly the ability of 
the  180-kD form of trkA to bind NGF by in vivo cross- 
linking experiments. 
The existence of only one trkA mRNA species in adult 
rat DRG suggests that the 180-kD form of trkA is post- 
translationally modified in  a  manner  different from the 
140-kD form. The 140-kD form of trkA itself is a highly 
glycosylated protein,  proceeding  from  an  80-kD  naked 
polypeptide through a  110-kD  glycosylated intermediate 
to a 140-kD fully processed form (39). The 180-kD form of 
trkA  can  be  precipitated by wheat  germ lectin agarose 
from DRG homogenates (M. D. Ehlers and V. E. Koliat- 
sos, unpublished observations), indicating that it is glyco- 
sylated as well.  However, preliminary experiments have 
failed to demonstrate an appreciable decrease in the ap- 
parent molecular mass of the 180-kD trkA species follow- 
ing  treatment  with  N-glycosidase F  (M.  D.  Ehlers  and 
V.E.  Koliatsos,  unpublished  observations),  raising  the 
possibility that some other type of posttranslational modifi- 
cation, perhaps  O-linked glycosylation, accounts for the 
increased apparent molecular mass.  Smaller amounts  of 
110- and 140-kD trkA forms can be seen in trkA immuno- 
blots from adult rat DRG. Whether these forms of trkA 
represent precursors to a fully processed 180-kD form or 
represent forms of trkA processed along a pathway differ- 
ent from that of the  180-kD  form remains  to be deter- 
mined. These lower molecular mass trkA species may also 
play a role in trkA signal transduction in adult sensory ax- 
ons and may, in fact, be retrogradely transported, but their 
relatively  low  abundance  in  adult  sensory  nerves  pre- 
cluded further analysis in this study. Although the 180-kD 
form of trkA is the predominant form of trkA in adult rat 
DRG, only the 110- and 140-kD forms of trkA are present 
in DRG from neonatal rats, suggesting that the posttrans- 
lational modification of trkA may be developmentally reg- 
ulated. 
NGF rapidly stimulates trkA tyrosine phosphorylation 
and activation of PLC-~I (27, 61), PI-3 kinase (43, 47), and 
SHC (46, 53, 55). These proteins subsequently induce the 
activation of ras, several serine/threonine kinases includ- 
ing the  Erks  (MAP  kinases),  Raf-1, B-Raf,  and p90rsk, 
and various immediate early genes that lead to the charac- 
teristic biological effects of NGF (4, 8, 44, 58, 63). It is un- 
known  whether  an  activated  signaling  molecule is  pro- 
duced at some point along this local signal transduction 
pathway at the nerve terminal, which is subsequently ret- 
rogradely transported to the perikarya. The fact that NGF 
itself is retrogradely transported in peripheral axons led to 
the initial hypothesis that the neurotrophin itself might act 
as its own intracellular signaling molecule (23). The later 
discovery that direct introduction of NGF into the cyto- 
plasm of PC12 cells does not result in neuronal differentia- 
tion (19)  suggested, however, that some other molecule 
with access to the cytoplasm must transduce the signal. 
In this study, ligation of the sciatic nerve of adult rats 
leads to an accumulation of trkA protein in the immedi- 
ately distal nerve segment. The paradigm of nerve ligation 
or crush with subsequent examination of the distal accu- 
mulation of axonal proteins has been previously used to 
demonstrate the retrograde transport of p75  NGFR by im- 
munocytochemical localization  (24).  The  mechanism  of 
retrograde transport is presumed to involve receptor inter- 
nalization in  an  endocytic fashion  (30).  It  has  been  re- 
ported that high-affinity NGF receptors internalize NGF 
in PC12 cells (2). In addition, the manipulation of target 
fields of neurons has been a time-honored practice in the 
study of target-derived trophic factors (10-13, 20), and, for 
a molecule to represent a neurotrophic signal, it must re- 
spond in a  physiologically appropriate manner to events 
that occur at the target field. Indeed, the injection of exog- 
enous NGF into the target field enhances the distal accu- 
mulation of trkA, whereas injection of anti-NGF antibod- 
ies greatly diminishes the distal accumulation of trkA in 
sciatic nerve axons. Thus, our findings are consistent with 
the idea that, upon binding NGF, trkA is endocytosed at 
the nerve terminal as a  coated vesicle and subsequently 
delivered to the  cell body by retrograde transport.  The 
finding that trkA is retrogradely transported in adult rat 
peripheral axons suggests that trkA might be acting as a 
signaling molecule between the nerve terminal and neu- 
ronal cell body. Indeed, immunoprecipitation of trk spe- 
cies from nerve segments immediately proximal and distal 
to the ligation site followed by phosphotyrosine immuno- 
blot analysis revealed that the trkA species in the distal 
segment was tyrosine phosphorylated, whereas the trkA 
species in the proximal segment was only weakly or not at 
all tyrosine phosphorylated. Studies in vitro have shown 
that  tyrosine  autophosphorylation of trkA  occurs  after 
NGF binding and is necessary for NGF signal transduction 
(26,  28,  37).  Our  results  imply that  retrogradely trans- 
ported trkA is an active kinase and are consistent with the 
notion that trkA can act as a retrograde neurotrophic sig- 
nal effector. The state of trkA as an active kinase in the 
axon suggests further that retrogradely transported trkA 
may continue to be bound to NGF. Interestingly, the ret- 
rograde transport of tyrosine phosphorylated trkA occurs 
in the absence of terminal field manipulation suggesting 
that NGF signaling is present, to at least some degree, in 
adult sensory neurons. The role of this steady-state trans- 
port of phosphorylated trkA in the survival or phenotypic 
maintenance of adult sensory neurons remains to be ex- 
amined. 
The injection of exogenous NGF into the target field in- 
creased the accumulation of tyrosine phosphorylated trkA 
in segments of sciatic nerve distal to a ligature, whereas in- 
jection of anti-NGF antibodies greatly diminished this ac- 
cumulation.  These  findings  support  the  idea  that  NGF 
binding to trkA at the nerve terminal leads to endocytosis 
and retrograde transport of an active tyrosine phosphory- 
lated receptor. Whether additional signaling molecules, in- 
cluding p75  NGFR, play a role in the retrograde transport of 
trkA, NGF, or a trkA-NGF complex was not addressed 
specifically in this  study.  Several scenarios can be envi- 
sioned, including NGF transport via a trkA monomer, via 
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plex.  Data presented in the present study are consistent with a 
model whereby NGF first binds  to trkA receptors at the nerve 
terminal, resulting in activation of the receptor by autophosphor- 
ylation. Receptor activation leads to local signaling  events that 
may affect processes such as neurite outgrowth. The NGF/NGF 
receptor complex is then internalized through endocytosis and 
retrogradely transported up the axon. The exact nature of the ret- 
rogradely  transported  NGF  signaling  complex is not clear but 
may involve only trkA in monomeric (top)  or dimeric  (middle) 
form or may involve both trkA and the low-affinity NGF recep- 
tor, p75 NCvR (bottom). 
a trkA homodimer, or perhaps via a trkA/p75 heterodimer 
(Fig.  5)  (16,  22).  This  last  possibility  is suggested  by  the 
known retrograde transport of p75  N°FR (24). The demon- 
stration of a necessary role of trkA in the above processes 
would require demonstrating that, in the absence of trkA, 
retrograde transport of NGF does not take place. The uti- 
lization of trkA null mice appears to be an ideal way to ad- 
dress  the  above  question  (50).  However,  the  principal 
NGF-transporting  sensory  system  (i.e.,  small  axons  that 
transmit pain  and  temperature)  degenerates  early in  the 
life  of these  animals.  Therefore, even if non-trkA recep- 
tors, such as p75  NcFR play a role in mediating NGF trans- 
port, there would be no conduit (or uptake site) for NGF 
trafficking in these mice. Similar problems complicate the 
study  of  the  role  of  p75  N°FR  in  NGF/trkA  retrograde 
transport using p75 null mice (33). Primary culture models 
of axonal transport using neurons from normal trkA null 
and p75  N~FR null animals may be used to circumvent these 
problems. 
The existence  of p75  NGFR, along with the expression of 
truncated splice forms of trkB and trkC lacking the kinase 
domain  (41,  59,  60)  as well  as  biologically  unresponsive 
full-length splice forms of trkC with amino acid inserts in 
the  kinase  domain,  have  added  much complexity  to  the 
field of neurotrophin signal transduction. Further compli- 
cations  are  introduced  by  the  differential  expression  of 
these splice variants in different tissues and at different de- 
velopmental stages (59, 60). The determination of the ex- 
act  nature  of the  retrogradely  transported neurotrophin/ 
receptor complexes will be a crucial step in understanding 
the physiological significance of the various forms of neu- 
rotrophin receptors and their roles in neurotrophin signal 
transduction. 
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